J&J partners HHS to speed-up coronavirus vaccine development
Johnson & Johnson (J&J) unit Janssen Pharmaceutical has partnered with the US Department of Health & Human Services (HHS) to speed-up the development of its investigational vaccine candidate against the new coronavirus disease, Covid-19.
The company and HHS’ Biomedical Advanced Research and Development Authority (BARDA) will work together in line with J&J’s multi-pronged initiative to fight the ongoing coronavirus outbreak.
Apart from the vaccine programme, the initiative will explore an antiviral molecules library to fast track the identification of potential Covid-19 therapies.
The vaccine candidate, based on Janssen’s AdVac and PER.C6 technologies, will have the potential to upscale production.
These technologies, previously used to develop and manufacture investigational Ebola vaccine, also created Zika, RSV and HIV vaccine candidates.
Johnson & Johnson chief scientific officer Paul Stoffels said: “This partnership will ensure that vital research is made possible at rapid speed and underscores the importance of public-private partnerships to tackle the worldwide novel coronavirus epidemic.
“We are also in discussions with other partners, that if we have a vaccine candidate with potential, we aim to make it accessible to China and other parts of the world.”
As part of the alliance, Janssen, as well as BARDA, will fund the research and development costs. Also, both the partners will leverage their resources to accelerate the initial stages of Janssen’s coronavirus vaccine programme.
BARDA will fund the development of a vaccine into Phase I clinical trials and holds options to provide additional funding to develop a hopeful candidate.
Meanwhile, Janssen will upscale the production and manufacturing. The company intends to forge stakeholder partnerships globally.
Earlier this month, Regeneron Pharmaceuticals also agreed to work with BARDA for the development of monoclonal antibodies targeting the new coronavirus.
source: https://pharmanewshq.com/jj-partners-hhs-to-speed-up-coronavirus-vaccine-development/
If you have any questions about this news, please do not hesitate to contact us.
Join Our Newsletter for Free
Latest News
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
LEARN MOREPfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
LEARN MOREJanux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
LEARN MORE